Active Substance Master File (ASMF)

An Active Substance Master File (ASMF) is a regulatory document format used in EU/EEA marketing-authorisation procedures that lets the manufacturer of an active pharmaceutical substance provide the full quality/manufacturing dataset for that substance directly and confidentially to the competent authority (a national medicines agency or the EMA), separately from the marketing authorisation application (MAA) submitted by the medicinal-product applicant or marketing authorisation holder (MAH). It was formerly known as the European Drug Master File (EDMF).

Why the ASMF procedure exists

An MAA/IMPD must demonstrate the quality of the active substance used in a medicinal product, which normally requires full disclosure of the manufacturing process, impurity profile, and validation data. Active-substance manufacturers are frequently third parties supplying multiple pharmaceutical companies, and disclosing that process know-how to every customer would expose commercially sensitive intellectual property. The ASMF procedure resolves this by splitting the dossier into two parts, submitted separately but reviewed together by the same assessor:

• Applicant’s Part (AP) — the non-confidential portion, submitted by (or on behalf of) the medicinal-product applicant/MAH as part of their own submission. It contains enough information (specification, analytical procedures, batch data, container/closure, stability summary) for the applicant to take responsibility for the suitability of the active substance’s quality control.
• Restricted Part (RP) — the confidential portion, submitted directly to the authority by the active-substance manufacturer (the “ASMF holder”). It contains the proprietary manufacturing details the holder does not want disclosed to the applicant: synthesis route, reaction conditions, in-process controls, and impurity-formation/validation data for critical steps.

The assessor evaluating the medicinal product’s marketing authorisation application has full access to both parts, so the confidentiality only operates between the ASMF holder and the applicant — not between the ASMF holder and the regulator.

Legal and procedural basis

The ASMF procedure is set out in EU pharmaceutical legislation (Directive 2001/83/EC, as amended, and its Annex I) and detailed in EMA’s Guideline on Active Substance Master File Procedure, which the EMA publishes and periodically revises as a scientific guideline. An ASMF is submitted for a specific active substance and is referenced by one or more MAAs; each new MAA referencing an existing ASMF requires a Letter of Access from the ASMF holder authorising that specific applicant to rely on the Restricted Part.

What operationally counts as an ASMF

A submission is functioning as an ASMF when all of the following hold:

• It covers a single active substance’s manufacture and quality control, not the finished medicinal product.
• It is split into an Applicant’s Part and a Restricted Part, submitted on the same procedural timeline but with different disclosure rights.
• The Restricted Part is submitted by the active-substance manufacturer directly to the authority, not routed through the medicinal-product applicant.
• It is referenced by (not a standalone substitute for) a marketing authorisation application, variation, or — in the investigational setting — an IMPD; the ASMF alone does not authorise anything.

Worked examples

Example 1 — generic applicant referencing a third-party API supplier. A generic-medicine applicant sources its active pharmaceutical ingredient (API) from an external manufacturer. Rather than requiring the API manufacturer to disclose its synthesis route to the generic applicant, the API manufacturer submits an ASMF: the Restricted Part (full synthesis and validation data) goes straight to the assessing authority, while the generic applicant submits the Applicant’s Part (specification and control data) as part of its own MAA, together with a Letter of Access authorising reliance on the Restricted Part.

Example 2 — same active substance, multiple MAAs. One active-substance manufacturer maintains a single ASMF that is referenced by several unrelated marketing authorisation applications from different companies over time, each obtaining its own Letter of Access — the manufacturer updates one master file rather than repeating full disclosure in every submission.

ASMF vs. related EU regulatory documents

ASMF vs. Certificate of Suitability (CEP). A CEP, issued by the European Directorate for the Quality of Medicines (EDQM), is an alternative route for demonstrating that an active substance complies with the relevant European Pharmacopoeia monograph; it substitutes for most of the quality data an ASMF would otherwise need to provide, but only where a suitable monograph exists and the manufacturing process is amenable to that route. An ASMF is used where no CEP applies or the substance/route falls outside what a CEP can cover.

ASMF vs. Investigational Medicinal Product Dossier (IMPD). The IMPD is the full quality/manufacturing/non-clinical/clinical data package submitted for a clinical trial application under the EU Clinical Trials Regulation. An ASMF is not a substitute for an IMPD — it is one input into an IMPD’s quality section: the IMPD can incorporate an ASMF by reference to cover the active-substance data, in the same way an ASMF is referenced by (rather than replacing) a full MAA.

ASMF (EU) vs. Drug Master File (DMF), specifically FDA Type II (US). The US FDA’s Drug Master File system serves a broadly analogous purpose — a Type II DMF lets a drug-substance manufacturer submit confidential manufacturing/quality information directly to FDA, referenced by an applicant’s IND/NDA/ANDA rather than disclosed to them. The two are procedurally distinct (different competent authorities, submission formats, and legal bases) but occupy the same functional role in their respective regulatory systems: protecting manufacturer know-how while still giving the reviewing authority full visibility. CASRAI does not yet have a dedicated dictionary entry for the US Drug Master File; this is a related, currently unlisted term worth adding separately given its status as the direct US procedural counterpart to the ASMF.

Counter-example

A quality dossier that is submitted in full, with no confidential/restricted split, directly within the MAA or IMPD itself (no separate manufacturer-submitted portion, no Letter of Access mechanism) is not an ASMF — it is simply the standard quality module of that submission. The defining feature of an ASMF is the two-part AP/RP structure with independent submission by the substance manufacturer, not merely “quality data about an active substance.”